Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PARP1 | P09874 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293046 | 0.88 | ALDH1A1 (0.46) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL12714430 | 0.81 | ALDH1A1 (0.40) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL2229693 | 0.79 | KDM4E (0.58) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL2229197 | 0.78 | ALDH1A1 (0.49) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL2230139 | 0.78 | ALDH1A1 (0.45) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL2231078 | 0.77 | ALDH1A1 (0.44) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL23407279 | 0.76 | ALDH1A1 (0.41) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL10484937 | 0.76 | GLS (0.62) | ALDH1A1GLSKDM4EGAASMN1; SMN2 | |
| SCHEMBL3045512 | 0.76 | ALDH1A1 (0.43) | ALDH1A1PARP1MEN1USP2KMT2A | |
| SCHEMBL2231071 | 0.76 | ALDH1A1 (0.53) | ALDH1A1PARP1MEN1USP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968602-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20140030317-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Occhiuti & Rohlicek LLP | 2014-01-30 | — | — | US | claimed |
| EP-2398325-A1 | METHODS OF TREATING INTESTINAL DISEASES AND INFLAMMATORY CONDITIONS RELATED TO HIV-AIDS | Bach Pharma, Inc. (US) | 2011-12-28 | — | — | EP | claimed |
| EP-2346522-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND NRF2 TRANSCRIPTION FACTORS | Bach Pharma, Inc. (US) | 2011-07-27 | — | — | EP | claimed |
| US-20100255077-A1 | METHODS OF TREATING INTESTINAL DISEASES AND INFLAMMATORY CONDITIONS RELATED TO HIV-AIDS | BACH PHARMA, INC. (US) | 2010-10-07 | — | — | US | claimed |
| WO-2010096686-A1 | METHODS OF TREATING INTESTINAL DISEASES AND INFLAMMATORY CONDITIONS RELATED TO HIV-AIDS | BACH PHARMA, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20100086531-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND Nrf2 TRANSCRIPTION FACTORS | BACH PHARMA INC. (US) | 2010-04-08 | — | — | US | claimed |
| US-7691819-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2010-04-06 | — | — | US | claimed |
| WO-2010036711-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND NRF2 TRANSCRIPTION FACTORS | BACH PHARMA INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20090036411-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. (US) | 2009-02-05 | — | — | US | claimed |
| EP-1924274-A4 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA INC (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1924274-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Bach Pharma, Inc (US) | 2008-05-28 | — | — | EP | claimed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | claimed |
| WO-2007018546-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20050288291-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2005-12-29 | — | — | US | claimed |
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | BRANDEIS UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20210161890-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN DYSFUNCTION | BACH PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20050288291-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161890-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN DYSFUNCTION | GRIK5, PMP22, GRIN2A | ALDH1A1 1868/4885PARP1 2018/4885MEN1 2046/4885 |
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | GPX1, GPX4, ENPEP | ALDH1A1 777/4885PARP1 3212/4885MEN1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.